The peptide 7B2 was first extracted from the porcine and human pituitary glands (Hsi et al., 1982; Seidah et al., 1983) . Subsequent studies by radioimmunoassay (RIA) revealed its presence outside the pituitary glands, that is, in the brain (Iguchi et al., 1984 (Iguchi et al., , 1985 , spinal cord (Suzuki et al., 1985) , pancreas (Suzuki et al., 1987) , gut, thyroid gland and adrenals (Iguchi et al., 1984) . This novel peptide 7B2 was also shown to be released by high potassium stimulation (Iguchi et al., 1984; Deng et al., 1986) or luteinizing hormonereleasing hormone (LH-RH) from the pituitary (Deng et al., 1986 ) and a pheochromocytoma cell line (PC 12) in vitro (Suzuki et al., 1986 a) , suggesting that 7B2 may be a peptide secreted by these endocrine glands. Because of the lack of a pure synthetic peptide, the function of this novel peptide has not yet been known.
In this ' study, we intended to assess The intra-and inter-assay coefficients of variation were 7 and 12%, respectively. RIAs of rLH and rTSH were performed by double-antibody procedures and using kits generously provided by the National Institute of Diabetes, Digestive and Kidney Disease (NIDDK), Bethesda, MD, USA, and calculated in terms of the standards for LH-RP-2 and TSH-RP-2.
The minimal detectable doses of rLH and rTSH were 18 and 25pg, respectively. The intra-and interassay coefficients of variations for these two RIAs were less than 10% and 15%, respectively.
The RIAs were performed according to the methods described in the protocols. All peptides and proteins were iodinated with sodium 125-I using the choloramine T method (Hunter & Greenwood. 1962) or lactoperoxidase method (Miyachi et al., 1972) .
Plasma free thyroxine concentrations were assessed with a commercial RIA kit supplied by Japan Diagnostic Products Co., Tokyo, Japan.
Statistical analysis The significance of difference between several groups of data was assessed by one way analysis of variance (ANOVA). A difference was considered significant if the resulting F value gave a probability of <0.05.
Differences between pairs of groups were then assessed by Student's unpaired t-test. Pituitary weight and 7B2 concentration in rats subjected to various endocrinological treatments. Abbreviations used in the figure are as follows; *: p<0.05; **: p<0.01 vs corresponding control value for each; Hyper: hyperthyroid rats treated with thyroxine; Hypo: hypothyroid rats treated with methyl mercaptoimidazole; Adx: adrenalectomized rats; Castrated: castrated rats; Ovx: ovariectomized rats; MSG: rats treated with monosodium glutamate neonatally. (Marcinkiewicz et al., 1985 (Marcinkiewicz et al., , 1986 Steel et al., 1988) . In human pituitaries and gonadotropinomas the coexistence of 7B2 and gonadotropin immunoreactivities was observed (Steel et al., 1988) .
Furthermore, the release of 7B2 from gonadotropes has been demonstrated to be prompted by high potassium and LH-RH (Iguchi et al., 1984; Deng et al., 1986; Natri et al., 1988) . These observations were consistent with the possibility that 7B2 is a novel secretory protein and has a close relation to gonadotropes.
On the other hand, Marcinkiewicz et al. (1986) reported that 7B2 immunoreactivity was found to be present not only in gonadotropes but also in thyrotropes. Iguchi et al. (1987) found that there were significant correlations between plasma 7B2 levels in cord blood and the body weight of neonates and plasma growth hormone levels in cord blood. Natri et al. (1988) also demonstrated that plasma 7B2 levels in patients with GH producing pituitary adenoma were elevated after intravenous GH-RH stimulation and that high potassium induced the release of 7B2 from the human somatotrope adenoma cells in vitro. These complicated results prompted us to study whether any changes could be observed in various endocrine situations. In this study, we failed to find any signicentrations during the estrous cycles. Although it was only of borderline significance, increased 7B2 concentrations were found in castrated and ovariectomized pituitaries. Steel et al. (1988) demonstrated that 7B2 immunoreactivity in ovariectomized pituitaries was more intense, more frequent and more extensive than that in control pituitaries.
In contrast to the present study, Deng et al. (1986) observed neither a significant increase in 7B2 content in castrated rat pituitaries nor a significant difference in 7B2 release from castrated rat anterior pituitary cells in vitro. In man, we have demonstrated plasma 7B2 release after intravenous LH-RH administration (Kobori. 1989 ) and high plasma 7B2 in patients with Turner's or Kleinfelter's syndrome (Suzuki et al., in preparation) .
Because LH and FSH immunoreactive cells have been reported to increase after ovariectomy (Ibrahim et al., 1986) and 7B2 immunoreactivity has been demonstrated to colocalize with gonadotropin immunoreactivities in the pituitary (Marcinkiewicz et al., 1985; Steel et al., 1988) , an increase in 7B2 content in the pituitary after gonadectomy seemed to be reasonable. The discrepancy in pituitary 7B2 content in these gonadectomized rats (Deng et al., 1986 Steel et al., 1988 ., might be due to the difference in rate of secretion of pituitary 7B2 to the circulation modified by LH-RH or other unknown secretagogues.
In rat pituitaries from adrenalectomized rats and thyroxine or MMI treated rats, no significant change in 7B2 content was found and this result is in accordance with the results of Steel et al. (1988) . The signitreated rats might, however, indicate that thyroid hormones could play a role in 7B2 metabolism in the brain. Paraenteral administration of MSG to neonatal rodents has been reported to result in a central nervous system lesion, restricted largely to neurons of the arcuate nucleus and to the retina (Olney 1969) . These rats show typical growth retardation, obesity and atrophy of optic nerve and endocrine glands.
It had been reported that anterior pituitary weight and GH content in the anterior pituitary was reduced (Ieiri et al., 1981) .
Recently, MSG has been reported to deplete immunoreactive growth hormone releasing factor (GRF) content in pituitary stalk-median eminence tissue (Bloch et al., 1984; Wakabayashi et al., 1986) . Not only GH but gonadotropin abnormalities were also demonstrated, though results were not uniform due to sex difference (Dada et al., 1984; Dada & Blake 1985; Inkster et al., 1985) . Furthermore, many other peptides such as adrenocorticotropin. (ACTH), beta endorphin (Krieger et al., 1979) , neuropeptide Y (Kererian & Pelletier 1986 ) and somatostatin (Depaolo & Steger 1985) , etc. had been shown to be influenced by the treatment.
A recent study demonstrated changes in 7B2 content in the hypothalamus and substantia nigra (Hashigami. 1989) . In the present study, in addition to these observations, a significant increase in pituitary 7B2 content was demonstrated.
As Dada et al. (1984) had reported for LH, the calculation of 7B2 content on the basis of the entire weight of the pituitaries showed no difference between the MSG treated rats and controls. This result suggest that the increase in 7B2 content per mg pituitaries might be of importance in maintaining the normal amount of 7B2 in small pituitaries. As the levels of the peptide in the tissue will reflect the balance between release from, synthesis and degradation within the tissue, measurements of tissue content of peptides therefore yield only limited information about the patterns of release. Further studies are obviously needed concerning 7B2 action and the pattern of release from MSG and gonadectomized rats and brain tissues from altered thyroid states.
